マレイミド/カルボン酸のクロスリンカー(PEGなし)
MAA1000およびMAA1020は異なる両末端官能性基を持つ試薬です。アミノ基とチオール基に対してそれぞれ反応性を持ちます。これらの試薬は免疫酵素複合体やハプテンキャリアを作製する際に有用です。MAA1000はスペーサーがベンゼンでない場合よりも、加水分解を受けにくく安定であるという特徴があります。
カルボニル基はバッファー中pH6.5-8.5の間で第一級アミンとアミド基を形成します。
マレイミドとチオールの反応はpH6.5-7.0の間で進行し、チオエステルを形成します。
マレイミド/カルボン酸クロスリンカー
表1. マレイミド/カルボン酸クロスリンカー一覧
| コード |
製品名 |
分子式 |
CAS |
分子量 |
内容量 |
名称 |
| MAA1000.0001 |
Mal-AMCHC-OSu |
C16H18N2O6 |
64987-85-5 |
334.33 |
1g |
trans-N-Succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate |
| MAA1000.0005 |
Mal-AMCHC-OSu |
C16H18N2O6 |
64987-85-5 |
334.33 |
5g |
trans-N-Succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate |
| MAA1020.0001 |
Mal-beta-Ala-OSu |
C11H10N2O6 |
55750-62-4 |
266.21 |
1g |
3-(Maleimido)propionic acid N-succinimidyl ester |
| MAA1020.0005 |
Mal-beta-Ala-OSu |
C11H10N2O6 |
55750-62-4 |
266.21 |
5g |
3-(Maleimido)propionic acid N-succinimidyl ester |
| MAA5400.0001 |
Mal-AMCHC-OH |
C12H15NO4 |
69907-67-1 |
237.25 |
1g |
trans-4-(maleimidomethyl)cyclohexane-1-carboxylic acid |
| MAA5400.0005 |
Mal-AMCHC-OH |
C12H15NO4 |
69907-67-1 |
237.25 |
5g |
trans-4-(maleimidomethyl)cyclohexane-1-carboxylic acid |
| MAA5400.0025 |
Mal-AMCHC-OH |
C12H15NO4 |
69907-67-1 |
237.25 |
25g |
trans-4-(maleimidomethyl)cyclohexane-1-carboxylic acid |
| PEG2135.0005 |
mal-COOH |
C7H7NO4 |
7423-55-4 |
169.13 |
5g |
3-(Maleimido-1-yl)propanoic acid |
| PEG2135.0025 |
mal-COOH |
C7H7NO4 |
7423-55-4 |
169.13 |
25g |
3-(Maleimido-1-yl)propanoic acid |
| PEG2135.9100 |
mal-COOH |
C7H7NO4 |
7423-55-4 |
169.13 |
100g |
3-(Maleimido-1-yl)propanoic acid |
マレイミド-PEG-カルボン酸
異なる両末端官能基を持つ試薬はカルボニル基によってターゲット分子のアミノ基と結合し、マレイミドがチオールと反応してチオエーテルを形成しさらに別の分子を結合することが可能です。多くの生体分子はアミノ基を持ち、さらにチオールを持っているもしくは何らかの手法によって組み込むことが可能です。
これらの試薬はハプテンとその担体の結合を活性化し、抗原性を抑制することで他の化合物との非特異的反応を減らすように設計されています。この特性は抗体の評価に直接つながるため非常に重要なパラメータです。PEG化されることによって親水性が増しながらも免疫原性が抑制されるため、さらなる応用が可能になります。
溶媒はDMAC、DMF、DMSO等が望ましいですが、水系溶媒でも可能です。ただしその際には、NHSなどの安定性を考慮に入れる必要があります。
マレイミド-PEG-カルボン酸
表2. マレイミド-PEG-カルボン酸一覧
| コード |
製品名 |
分子式 |
CAS |
分子量 |
内容量 |
名称 |
| PEG1058.0001 |
mal-PEG-COOH |
- |
- |
10000 |
1g |
alpha-Maleimido-omega-carboxy poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
| PEG1058.0500 |
mal-PEG-COOH |
- |
- |
10000 |
500mg |
alpha-Maleimido-omega-carboxy poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
| PEG1059.0001 |
mal-PEG-COOH |
- |
- |
3000 |
1g |
alpha-Maleimido-omega-carboxy poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
| PEG1059.0500 |
mal-PEG-COOH |
- |
- |
3000 |
500mg |
alpha-Maleimido-omega-carboxy poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
| PEG1060.0001 |
mal-PEG-COOH |
- |
- |
5000 |
1g |
alpha-Maleimido-omega-carboxy poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
| PEG1060.0500 |
mal-PEG-COOH |
- |
- |
5000 |
500mg |
alpha-Maleimido-omega-carboxy poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
| PEG1061.0001 |
mal-PEG-NHS |
- |
- |
10000 |
1g |
alpha-Maleimido-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
| PEG1061.0500 |
mal-PEG-NHS |
- |
- |
10000 |
500mg |
alpha-Maleimido-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
| PEG1062.0001 |
mal-PEG-NHS |
- |
- |
3000 |
1g |
alpha-Maleimido-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
| PEG1062.0500 |
mal-PEG-NHS |
- |
- |
3000 |
500mg |
alpha-Maleimido-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
| PEG1063.0001 |
mal-PEG-NHS |
- |
- |
5000 |
1g |
alpha-Maleimido-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
| PEG1063.0500 |
mal-PEG-NHS |
- |
- |
5000 |
500mg |
alpha-Maleimido-omega-carboxy succinimidyl ester poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
| PEG1209.0001 |
mal-PEG(27)-NHS |
C70H127N3O35 |
- |
1570.76 |
1g |
alpha-Maleimido-omega-carboxy succinimidyl ester 27(ethylene glycol) |
| PEG1209.0100 |
mal-PEG(27)-NHS |
C70H127N3O35 |
- |
1570.76 |
100mg |
alpha-Maleimido-omega-carboxy succinimidyl ester 27(ethylene glycol) |
| PEG1550.0001 |
mal-dPEG(12)-NHS |
C38H63N3O19 |
756525-92-5 |
865.92 |
1g |
1-Maleimido-3-oxo-7,10,13,16,19,22,25,28,31,34,37,40-dodecaoxa-4-azatritetracontan-43-oic acid succinimidyl ester |
| PEG1550.0100 |
mal-dPEG(12)-NHS |
C38H63N3O19 |
756525-92-5 |
865.92 |
100mg |
1-Maleimido-3-oxo-7,10,13,16,19,22,25,28,31,34,37,40-dodecaoxa-4-azatritetracontan-43-oic acid succinimidyl ester |
| PEG1555.0001 |
mal-PEG(2)-COOH |
C14H20N2O7 |
756525-98-1 |
328.32 |
1g |
3-(2-(2-(3-Maleimidopropanamido)ethoxy)ethoxy)propanoic acid |
| PEG1555.0100 |
mal-PEG(2)-COOH |
C14H20N2O7 |
756525-98-1 |
328.32 |
100mg |
3-(2-(2-(3-Maleimidopropanamido)ethoxy)ethoxy)propanoic acid |
| PEG1560.0001 |
mal-PEG(2)-NHS |
C18H23N3O9 |
955094-26-5 |
425.39 |
1g |
3-(2-(2-(3-Maleimidopropanamido)ethoxy)ethoxy)propanoic acid succinimidyl ester |
| PEG1560.0100 |
mal-PEG(2)-NHS |
C18H23N3O9 |
955094-26-5 |
425.39 |
100mg |
3-(2-(2-(3-Maleimidopropanamido)ethoxy)ethoxy)propanoic acid succinimidyl ester |
| PEG1565.0001 |
mal-dPEG(24)-NHS |
C62H111N3O31 |
756525-92-5 |
1394.55 |
1g |
alpha-Maleimido-24(ethylene glycol)-omega-propionic acid succinimidyl ester |
| PEG1565.0100 |
mal-dPEG(24)-NHS |
C62H111N3O31 |
756525-92-5 |
1394.55 |
100mg |
alpha-Maleimido-24(ethylene glycol)-omega-propionic acid succinimidyl ester |
| PEG1570.0001 |
mal-dPEG(4)-COOH |
C18H28N2O9 |
1263045-16-4 |
416.42 |
1g |
1-Maleimido-3-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oic acid |
| PEG1570.0100 |
mal-dPEG(4)-COOH |
C18H28N2O9 |
1263045-16-4 |
416.42 |
100mg |
1-Maleimido-3-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oic acid |
| PEG1575.0001 |
mal-dPEG(4)-NHS |
C22H31N3O11 |
756525-99-2 |
513.5 |
1g |
15-[(3-Maleimid-1-yl)propanoylamido]-4,7,10,13-tetraoxa-pentadecanoyl succinimidyl ester |
| PEG1575.0100 |
mal-dPEG(4)-NHS |
C22H31N3O11 |
756525-99-2 |
513.5 |
100mg |
15-[(3-Maleimid-1-yl)propanoylamido]-4,7,10,13-tetraoxa-pentadecanoyl succinimidyl ester |
| PEG1585.0001 |
mal-dPEG(6)-NHS |
C26H39N3O13 |
1137109-21-7 |
601.6 |
1g |
25-Maleimido-23-oxo-4,7,10,13,16,19-hexaoxa-22-azapentacosanoic acid succinimidyl ester |
| PEG1585.0100 |
mal-dPEG(6)-NHS |
C26H39N3O13 |
1137109-21-7 |
601.6 |
100mg |
25-Maleimido-23-oxo-4,7,10,13,16,19-hexaoxa-22-azapentacosanoic acid succinimidyl ester |
| PEG1590.0001 |
mal-dPEG(8)-NHS |
C30H47N3O15 |
756525-93-6 |
689.71 |
1g |
1-Maleimido-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid succinimidyl ester |
| PEG1590.0100 |
mal-dPEG(8)-NHS |
C30H47N3O15 |
756525-93-6 |
689.71 |
100mg |
1-Maleimido-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid succinimidyl ester |
| PEG1600.0001 |
mal-dPEG(24)-COOH |
C58H108N2O29 |
871133-36-7 |
1297.47 |
1g |
alpha-Maleimido-24(ethylene glycol)-omega-propionic acid |
| PEG1600.0100 |
mal-dPEG(24)-COOH |
C58H108N2O29 |
871133-36-7 |
1297.47 |
100mg |
alpha-Maleimido-24(ethylene glycol)-omega-propionic acid |
| PEG1615.0001 |
mal-dPEG(8)-COOH |
C26H44N2O13 |
1334177-86-4 |
592.63 |
1g |
1-Maleimido-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid |
| PEG1615.0100 |
mal-dPEG(8)-COOH |
C26H44N2O13 |
1334177-86-4 |
592.63 |
100mg |
1-Maleimido-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid |
| PEG2125.0001 |
mal-PEG(12)-COOH |
C34H60N2O17 |
871133-36-7 |
768.84 |
1g |
3-(2-(2-(3-(Maleimido-1-yl)propanamido)ethoxy)ethoxy)propanoic acid |
| PEG2125.0100 |
mal-PEG(12)-COOH |
C34H60N2O17 |
871133-36-7 |
768.84 |
100mg |
3-(2-(2-(3-(Maleimido-1-yl)propanamido)ethoxy)ethoxy)propanoic acid |
| PEG3830.0000 |
mal-dPEG™(16)-NHS |
C46H79N3O23 |
756525-92-5 |
1042.13 |
0mg |
alpha-Maleimido-omega-(succinimidyl propionate) hexadeca(ethylene glycol) |
| PEG3850.0100 |
mal-dPEG™(6)-COOH |
C22H36N2O11 |
1334177-79-5 |
504.53 |
100mg |
alpha-Maleimido-hexa(ethylene glycol)-omega-propionic acid |
| PEG3850.1000 |
mal-dPEG™(6)-COOH |
C22H36N2O11 |
1334177-79-5 |
504.53 |
1g |
alpha-Maleimido-hexa(ethylene glycol)-omega-propionic acid |
| PEG3860.0000 |
mal-dPEG™(16)-COOH |
C42H76N2O21 |
871133-36-7 |
945.05 |
0mg |
alpha-Maleimido-hexadeca(ethylene glycol)-omega-propionic acid |
| PEG3870.0000 |
mal-dPEG™(20)-COOH |
C50H92N2O25 |
871133-36-7 |
1121.26 |
100mg |
alpha-Maleimido-20(ethylene glycol)-omega-propionic acid |
| PEG4870.0001 |
Mal-O2Oc-OH |
C10H13NO6 |
173323-23-4 |
243.21 |
1g |
{2-[2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}acetic acid |
| PEG4870.0005 |
Mal-O2Oc-OH |
C10H13NO6 |
173323-23-4 |
243.21 |
5g |
{2-[2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}acetic acid |
| PEG4870.0250 |
Mal-O2Oc-OH |
C10H13NO6 |
173323-23-4 |
243.21 |
250mg |
{2-[2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}acetic acid |
参考文献
▷ Bioconjugate Techniques; G. T. Hermanson; 2nd Edition; Elsevier 2008; 276-335 and 718-722: protocols; 788: hapten-carrier conjugation; 871: liposome conjugation; 883: antibody liposome conjugation; ISBN 978-0-12-370501-3
マレイミド-PEG-アミン/ヒドラジン
これら異なる両末端官能基を持つタンパク質やペプチド修飾用の試薬はカルボニル基を持つターゲット分子と結合し次いでマレイミドがチオールと反応します。PEG化されることによって親水性が増しながらも免疫原性が抑制されるため、さらなる応用が可能になります。
系中で形成されるヒドラジンは、中性および塩基性条件で安定ですが、酸性水溶液中で加水分解されます。この特性は大いに薬剤デリバリーの分野で有用です。
マレイミド-PEG-アミン/ヒドラジン
表3. マレイミド-PEG-アミン/ヒドラジン一覧
| コード |
製品名 |
分子式 |
CAS |
分子量 |
内容量 |
名称 |
| PEG1580.0001 |
mal-dPEG(4)-NHNH-Boc |
C23H38N4O10 |
1127247-28-2 |
530.57 |
1g |
1-Maleimido-3-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oyl-(N'-t-butyloxycarbonyl)hydrazid |
| PEG1580.0100 |
mal-dPEG(4)-NHNH-Boc |
C23H38N4O10 |
1127247-28-2 |
530.57 |
100mg |
1-Maleimido-3-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oyl-(N'-t-butyloxycarbonyl)hydrazid |
| PEG2105.0001 |
MP-EDA*TFA |
C9H14N3O3*C2F3O2 |
11550-02-00 |
212.23*113.02 |
1g |
2-(3-(Maleimid-1-yl)propanamido)ethanaminium trifluoracetat |
| PEG2105.0100 |
MP-EDA*TFA |
C9H14N3O3*C2F3O2 |
11550-02-00 |
212.23*113.02 |
100mg |
2-(3-(Maleimid-1-yl)propanamido)ethanaminium trifluoracetat |
| PEG3880.0100 |
mal-dPEG™(8)-NHNH-Boc |
C31H54N4O14 |
1334169-98-0 |
706.78 |
100mg |
alpha-Maleimido-omega-(t-butyloxycarbonylhydrazidopropionate) octa(ethylene glycol) |
| PEG3880.1000 |
mal-dPEG™(8)-NHNH-Boc |
C31H54N4O14 |
1334169-98-0 |
706.78 |
1g |
alpha-Maleimido-omega-(t-butyloxycarbonylhydrazidopropionate) octa(ethylene glycol) |
| PEG3890.0100 |
mal-dPEG™(12)-NHNH-Boc |
C39H70N4O18 |
1334169-99-1 |
882.99 |
100mg |
alpha-Maleimido-omega-(t-butyloxycarbonylhydrazidopropionate) dodeca(ethylene glycol) |
| PEG3890.1000 |
mal-dPEG™(12)-NHNH-Boc |
C39H70N4O18 |
1334169-99-1 |
882.99 |
1g |
alpha-Maleimido-omega-(t-butyloxycarbonylhydrazidopropionate) dodeca(ethylene glycol) |
参考文献
▷ Bioconjugate Techniques; G. T. Hermanson; 2nd Edition; Elsevier2008; 30; ISBN 978-0-12-370501-3
メトキシ-PEG-マレイミド
マレイミドを末端に持ち、チオールと高い反応性を示します。結合分子に親水性を付与し、凝集を抑制します。
メトキシ-PEG-マレイミド
表4. メトキシ-PEG-マレイミド一覧
| コード |
製品名 |
分子式 |
CAS |
分子量 |
内容量 |
名称 |
| PEG1146.0001 |
MeO-PEG-mal |
- |
- |
10000 |
1g |
alpha-Methoxy-omega-ethyl-maleimide poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
| PEG1146.0005 |
MeO-PEG-mal |
- |
- |
10000 |
5g |
alpha-Methoxy-omega-ethyl-maleimide poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
| PEG1147.0001 |
MeO-PEG-mal |
- |
- |
2000 |
1g |
alpha-Methoxy-omega-ethyl-maleimide poly(ethylene glycol) (PEG-MW 2.000 Dalton) |
| PEG1147.0005 |
MeO-PEG-mal |
- |
- |
2000 |
5g |
alpha-Methoxy-omega-ethyl-maleimide poly(ethylene glycol) (PEG-MW 2.000 Dalton) |
| PEG1148.0001 |
MeO-PEG-mal |
- |
- |
20000 |
1g |
alpha-Methoxy-omega-ethyl-maleimide poly(ethylene glycol) (PEG-MW 20.000 Dalton) |
| PEG1148.0005 |
MeO-PEG-mal |
- |
- |
20000 |
5g |
alpha-Methoxy-omega-ethyl-maleimide poly(ethylene glycol) (PEG-MW 20.000 Dalton) |
| PEG1149.0001 |
MeO-PEG-mal |
- |
- |
5000 |
1g |
alpha-Methoxy-omega-ethyl-maleimide poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
| PEG1149.0005 |
MeO-PEG-mal |
- |
- |
5000 |
5g |
alpha-Methoxy-omega-ethyl-maleimide poly(ethylene glycol) (PEG-MW 5.000 Dalton) |
| PEG1150.0001 |
MeO-PEG-mal |
- |
- |
750 |
1g |
alpha-Methoxy-omega-ethyl-maleimide poly(ethylene glycol) (PEG-MW 750 Dalton) |
| PEG1150.0005 |
MeO-PEG-mal |
- |
- |
750 |
5g |
alpha-Methoxy-omega-ethyl-maleimide poly(ethylene glycol) (PEG-MW 750 Dalton) |
| PEG1665.0001 |
MeO-dPEG(12)-mal |
C32H58N2O15 |
88504-24-9 |
710.81 |
1g |
Maleimidyl-N-(2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-yl)propanamide |
| PEG1665.0100 |
MeO-dPEG(12)-mal |
C32H58N2O15 |
88504-24-9 |
710.81 |
100mg |
Maleimidyl-N-(2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-yl)propanamide |
| PEG1675.0001 |
MeO-dPEG(24)-mal |
C56H106N2O27 |
88504-24-9 |
1239.47 |
1g |
alpha-Methoxy-omega-maleimidyl-propanamide 24(ethylene glycol) |
| PEG1675.0100 |
MeO-dPEG(24)-mal |
C56H106N2O27 |
88504-24-9 |
1239.47 |
100mg |
alpha-Methoxy-omega-maleimidyl-propanamide 24(ethylene glycol) |
| PEG2375.0001 |
MeO-PEG(4)-mal |
C16H26N2O7 |
1263044-81-0 |
358.39 |
1g |
alpha-Methoxy-omega-maleimido tetra(ethylene glycol) |
| PEG2375.0100 |
MeO-PEG(4)-mal |
C16H26N2O7 |
1263044-81-0 |
358.39 |
100mg |
alpha-Methoxy-omega-maleimido tetra(ethylene glycol) |
| PEG2380.0001 |
MeO-PEG(8)-mal |
C24H42N2O11 |
1334169-90-2 |
534.6 |
1g |
alpha-Methoxy-omega-maleimido octa(ethylene glycol) |
| PEG2380.0100 |
MeO-PEG(8)-mal |
C24H42N2O11 |
1334169-90-2 |
534.6 |
100mg |
alpha-Methoxy-omega-maleimido octa(ethylene glycol) |
| PEG3360.0100 |
MeO-dPEG™(36)-mal |
C80H154N2O39 |
88504-24-9 |
1768.07 |
100mg |
alpha-Methoxy-omega-maleimidyl-propanamide 36(ethylene glycol) |
| PEG3360.1000 |
MeO-dPEG™(36)-mal |
C80H154N2O39 |
88504-24-9 |
1768.07 |
1g |
alpha-Methoxy-omega-maleimidyl-propanamide 36(ethylene glycol) |
| PEG3370.0100 |
MeO-dPEG™(48)-mal |
C104H202N2O51 |
88504-24-9 |
2296.7 |
100mg |
alpha-Methoxy-omega-maleimidyl-propanamide 48(ethylene glycol) |
| PEG3370.1000 |
MeO-dPEG™(48)-mal |
C104H202N2O51 |
88504-24-9 |
2296.7 |
1g |
alpha-Methoxy-omega-maleimidyl-propanamide 48(ethylene glycol) |
参考文献
▷ Bioconjugate Techniques; G. T. Hermanson; 2nd Edition; Elsevier2008; 30; ISBN 978-0-12-370501-3
ビスマレイミド-PEG
ビスマレイミド-PEG
表5. ビスマレイミド-PEG一覧
| コード |
製品名 |
分子式 |
CAS |
分子量 |
内容量 |
名称 |
| PEG1126.0001 |
mal-PEG-mal |
- |
- |
10000 |
1g |
alpha,omega-Bis-maleimido poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
| PEG1126.0005 |
mal-PEG-mal |
- |
- |
10000 |
5g |
alpha,omega-Bis-maleimido poly(ethylene glycol) (PEG-MW 10.000 Dalton) |
| PEG1127.0001 |
mal-PEG-mal |
- |
- |
2000 |
1g |
alpha,omega-Bis-maleimido poly(ethylene glycol) (PEG-MW 2.000 Dalton) |
| PEG1127.0005 |
mal-PEG-mal |
- |
- |
2000 |
5g |
alpha,omega-Bis-maleimido poly(ethylene glycol) (PEG-MW 2.000 Dalton) |
| PEG1128.0001 |
mal-PEG-mal |
- |
- |
20000 |
1g |
alpha,omega-Bis-maleimido poly(ethylene glycol) (PEG-MW 20.000 Dalton) |
| PEG1128.0005 |
mal-PEG-mal |
- |
- |
20000 |
5g |
alpha,omega-Bis-maleimido poly(ethylene glycol) (PEG-MW 20.000 Dalton) |
| PEG1129.0001 |
mal-PEG-mal |
- |
- |
3000 |
1g |
alpha,omega-Bis-maleimido poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
| PEG1129.0005 |
mal-PEG-mal |
- |
- |
3000 |
5g |
alpha,omega-Bis-maleimido poly(ethylene glycol) (PEG-MW 3.000 Dalton) |
| PEG1130.0001 |
mal-PEG-mal |
- |
- |
6000 |
1g |
alpha,omega-Bis-maleimido poly(ethylene glycol) (PEG-MW 6.000 Dalton) |
| PEG1130.0005 |
mal-PEG-mal |
- |
- |
6000 |
5g |
alpha,omega-Bis-maleimido poly(ethylene glycol) (PEG-MW 6.000 Dalton) |
| PEG1485.0001 |
mal-dPEG(3)-mal |
C24H34N4O9 |
756525-89-0 |
522.55 |
1g |
Bis-(1,13-(3-maleimidopropionyl)amido)-4,7,10-trioxatridecane |
| PEG1485.0050 |
mal-dPEG(3)-mal |
C24H34N4O9 |
756525-89-0 |
522.55 |
50mg |
Bis-(1,13-(3-maleimidopropionyl)amido)-4,7,10-trioxatridecane |
| PEG2085.0001 |
mal-PEG(11)-mal |
C38H62N4O17 |
854753-78-9 |
846.92 |
1g |
alpha,omega-Bis-[(3-maleimid-1-yl)propanoylamido] undeca(ethylene glycol) |
| PEG2085.0050 |
mal-PEG(11)-mal |
C38H62N4O17 |
854753-78-9 |
846.92 |
50mg |
alpha,omega-Bis-[(3-maleimid-1-yl)propanoylamido] undeca(ethylene glycol) |
参考文献
▷ Bioconjugate Techniques; G. T. Hermanson; 2nd Edition; Elsevier2008; 30; ISBN 978-0-12-370501-3